ArticleExperimental & molecular medicine2026
KSHV vIRF3-PKM2 interaction induces SMAD5 acetylation, promoting Kaposi's sarcoma progression.
Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Kaposi's sarcoma (KS), induced by Kaposi's sarcoma-associated herpesvirus (KSHV), is a multicentric tumor of lymphatic endothelial origin. However, the fundamental molecular mechanisms underlying the KS progression remain poorly understood. Here we found that interaction between KSHV vIRF3 and PKM2 controls the metabolic switch of lymphatic endothelial cells (LECs), inducing disseminated visceral KS in xenograft models of KSHV-infected LECs. Mechanistically, vIRF3-PKM2 interaction elevates intracellular acetyl coenzyme A (acetyl-CoA) level by augmenting the PKM2 enzymatic activity, leading to SMAD5 acetylation, which contributes to the endothelia-to-mesenchymal transition of LECs. Notably, a vIRF3-derived short peptide acts as a potent and selective PKM2 antagonist, effectively regressing KS progression. Collectively, these results suggest that vIRF3 plays a pivotal role in KS malignancy by linking acetyl-CoA metabolic reprogramming to cancer progression.
Identifiers
42834109What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.